Opinion
Video
Cedric Pobel, MD: Key takeaways from PEACE-1 ancillary study
Author(s):
Key Takeaways
- Combining AR and neuroendocrine marker expressions helps identify metastatic castration-sensitive prostate cancer (mCSPC) patient subgroups with different prognoses.
- Baseline AR and neuroendocrine marker expressions in mCSPC patients correlate with a worse prognosis.
"Both AR and neuroendocrine marker expressions in mCSPC patients at baseline is associated with worse prognosis," says Cedric Pobel, MD.
In this video, Cedric Pobel, MD, shares future work and key take-home messages from the study, “Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer: An Ancillary Study of the PEACE-1 Phase 3 Trial,” which was presented at the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain. Pobel is a medical oncologist and PhD student at Gustave Roussy Institute in Paris, France.
Video Transcript:
For this course, there's also a transcriptomic analysis going on for which we're going to have results soon. We wanted to explore all these results at immunochemistry and genomic level, on a gene expression level.
Take home message, I would say that combining AR and neuroendocrine marker expressions allows the identification of mCSPC patient subgroups with different outcomes. Both AR and neuroendocrine marker expressions in mCSPC patients at baseline is associated with worse prognosis. The signature with at least 2 genes alterated among T53, PTEN, and RB1 is also associated with worse prognosis, and no biomarker was pronounced for abiraterone benefits in this PEACE-1 patients.
This transcription has been edited for clarity.
